Most clinical and preclinical studies involve cetuximab and panitumumab conjugated with IRdye700 (cetuximab-IRdye700 and panitumumab-IRdye700) for targeting the membrane receptor epidermal growth factor receptor (EGFR) overexpressing cancer cells [13,28]. Here, EGFR is linked to cancer.